Vimarsana
Biggest News Aggregation in the World

Page 43 - Resented News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Resented. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Resented Today - Breaking & Trending Today

Thai Oil : Recently, Thai Oil Public Company Limited was presented the "Honorable Mention Award" from "the 11th NACC Integrity Awards 2022" - Vimarsana News

Thai Oil : Recently, Thai Oil Public Company Limited was presented the "Honorable Mention Award" from "the 11th NACC Integrity Awards 2022"

Thaioil won the Honorable MentionAward from the 11th NACC Integrity Awards 2022 Recently, Thai Oil Public Company Limited was presented the "Honorable... | April 5, 2023

BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference - Vimarsana News

BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB and its partner Eisai has presented new findings on lecanemab , an anti-amyloid beta protofibril antibody for the treatment of Alzheimer's... | April 3, 2023

BioArctic: New lecanemab-data presented at the AD/PD 2023 conference - Vimarsana News

BioArctic: New lecanemab-data presented at the AD/PD 2023 conference

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI)

Pioneer Property : PPG 2022 report on salary and other remuneration - Vimarsana News

Pioneer Property : PPG 2022 report on salary and other remuneration

Presented to the Annual General Meeting 25.04.2023 REPORT ON SALARIES AND OTHER REMUNERATION TO LEADING PERSONNEL IN PIONEER PROPERTY GROUP ASA FOR ... | April 3, 2023

Travere Therapeutics, Inc.: Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 - Vimarsana News

Travere Therapeutics, Inc.: Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal